Sangamo Therapeutics

Sangamo Therapeutics, Inc. is an American biotechnology company based in Brisbane, California. The company focuses on the research and development of genomic therapies using gene editing, gene therapy, cell therapy, and gene regulation technologies. Sangamo Therapeutics aims to treat a variety of genetic diseases, including hemophilia, sickle cell disease, and beta-thalassemia.

History

Sangamo Therapeutics was founded in 1995 by Edward Lanphier. The company initially focused on the development of zinc finger nucleases (ZFNs), a type of engineered DNA-binding protein that facilitates targeted editing of the genome. Over the years, Sangamo has expanded its technology platform to include other gene-editing tools such as CRISPR and TALENs.

Technology

Sangamo Therapeutics utilizes several advanced technologies in its research and development efforts:

• Zinc Finger Nucleases (ZFNs): ZFNs are engineered proteins that create double-strand breaks in DNA at specific locations, allowing for targeted gene editing.
• CRISPR/Cas9: A widely used gene-editing technology that enables precise modifications to the genome.
• TALENs: Transcription activator-like effector nucleases, another type of engineered protein used for gene editing.
• AAV Vectors: Adeno-associated virus vectors are used for delivering gene therapy to target cells.

Pipeline

Sangamo Therapeutics has a diverse pipeline of therapeutic candidates in various stages of development:

• SB-525: A gene therapy for hemophilia A in collaboration with Pfizer.
• ST-400: A gene-editing therapy for beta-thalassemia in collaboration with Sanofi.
• BIVV003: A gene-editing therapy for sickle cell disease in collaboration with Sanofi.
• TX200: A CAR-Treg cell therapy for the treatment of solid organ transplant rejection.

Collaborations

Sangamo Therapeutics has established several strategic collaborations with leading pharmaceutical and biotechnology companies to advance its research and development programs. Notable partners include Pfizer, Sanofi, and Biogen.

Facilities

The company's headquarters are located in Brisbane, California, with additional research and manufacturing facilities in Richmond, California and Valbonne, France.

See also

• Gene therapy
• Gene editing
• Biotechnology
• CRISPR
• Zinc finger nucleases
• Cell therapy